Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin
The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X obtained from plasma or by means of genetic engineering, which can be at least partially in the activated state, and coagulation factor Xla obtained from plasma or by means of genetic engineering, and (C) phospholipids which are safe from prions and contribute to the clotting process, said phospholipids being optionally contained in liposomes.
1. A pharmaceutical composition comprising:
(A) an isolated prothrombin (coagulation factor II),
(B) isolated virus-safe coagulation factors V, VIII, IX, X, and XIa, and
(C) prion-safe, coagulation-active phospholipids wherein the coagulation factors are present in amounts capable of together generating thrombin.
2. The pharmaceutical composition according to claim 1 further comprising coagulation factor VII or a mixture of coagulation factors VII and VIIa.
3. The pharmaceutical composition according to claim 1 , further comprising a genetically engineered tissue factor as such or in relipidated form.
4. The pharmaceutical composition according to claim 1 wherein the coagulation factors are produced exclusively from the blood plasma, from an allogenic sources, or from the corresponding genetically engineered coagulation factors or activated coagulation factors.
5. The pharmaceutical composition according to claim 1 wherein prothrombin, coagulation factors V, VIII, IX, X, XIa, and, when present, coagulation factors VII and VIIa, as well as tissue factor have been rendered virally safe by virus inactivation and/or virus partitioning.
6. The pharmaceutical composition according to claim 1 which is in deep-frozen or freeze-dried form.
7. A medicinal product capable of generating thrombin comprising the pharmaceutical preparation according to claim 1 .
8. The medicinal product according to claim 7 which is in deep-frozen or in freeze-dried form.
9. The medicinal product according to claim 7 which further comprises thrombin in an amount to yield no more than 1 U of thrombin per mL after thawing or reconstitution.
10. The medicinal product of claim 7 , wherein the medicinal product coagulates within 30 to 300 seconds when the medicinal product is mixed with a fibrinogen-containing product prior to application, whereby thrombin is generated.
11. The medicinal product of claim 10 wherein the prion-safe, coagulation-active phospholipids are from plant origin or plant and synthetic origin, in a ratio of phosphatidylcholines to phosphatidylserines of 3 to 1, or of phosphatidylcholines to phosphatidylserines to phosphatidylethanolamines of 2 to 2 to 1.
12. The medicinal product of claim 11 , wherein the phospholipid is prepared by mixing with kaolin and irradiating with ultrasound, for use in activating prothrombin complex-containing solutions.
13. The medicinal product of claim 7 , wherein the medicinal product coagulates within 3 to 10 seconds when the medicinal product is mixed with a fibrinogen-containing product prior to application, whereby thrombin is generated.
14. The medicinal product according to claim 7 , wherein the comprised phospholipids are prepared using a phospholipid emulsion which has been subjected to ultrasonic irradiation.
15. The medicinal product according to claim 14 , where the emulsion is further subjected to sterile filtration.
16. The medicinal product according to claim 15 , wherein the phospholipid is prepared by mixing with kaolin and irradiating with ultrasound, for use in activating prothrombin complex-containing solutions.
17. The medicinal product according to claim 14 , wherein the phospholipid is prepared by mixing with kaolin and irradiating with ultrasound, for use in activating prothrombin complex-containing solutions.
18. The medicinal product according to claim 7 , prepared using an effective calcium ion concentration ranging from 10 mM to 640 mM.
19. A medicinal product containing thrombin comprising the pharmaceutical preparation according to claim 1 .
20. The medicinal product according to claim 19 which is in deep-frozen or freeze-dried form.
21. The pharmaceutical composition according to claim 1 , wherein coagulation factor XIa is generated from coagulation factor XI by coagulation factor XIIa on negatively charged surfaces, and wherein coagulation factor XIIa is generated from coagulation factor XII by the addition of virally inactivated or virally safe kallikrein, or virally inactivated or virally safe prekallikrein with virally safe prekallikrein activators.
22. The pharmaceutical composition according to claim 1 which further comprises thrombin-activatable fibrinolysis inhibitor or thrombin-activatable fibrinolysis inhibitor and coagulation factor XIII in addition to prothrombin complexes and which, after activation of prothrombin, contains at least 3 U (50 μg) activated thrombin-activatable fibrinolysis inhibitor or 3 U activated thrombin-activatable fibrinolysis inhibitor and 5 U coagulation factor XIIIa per 1000 U thrombin.
23. The pharmaceutical composition according to claim 1 comprising prion-safe, coagulation-active phospholipids from plant origin or plant and synthetic origin, in a ratio of phosphatidylcholines to phosphatidylserines of 3 to 1, or of phosphatidyl-cholines to phosphatidylserines to phosphatidylethanolamines of 2 to 2 to 1.
24. The pharmaceutical composition according to claim 1 , wherein the comprised phospholipids are prepared using a phospholipid emulsion which has been subjected to ultrasonic irradiation.
25. The pharmaceutical composition according to claim 24 , where the emulsion is further subjected to sterile filtration.
26. The pharmaceutical composition according to claim 25 , wherein the phospholipid is prepared by mixing with kaolin and irradiating with ultrasound, for use in activating prothrombin complex-containing solutions.
27. The pharmaceutical composition according to claim 24 , wherein the phospholipid is prepared by mixing with kaolin and irradiating with ultrasound, for use in activating prothrombin complex-containing solutions.